Efficacy and safety of recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial.
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2016
At a glance
- Drugs Anakinra (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Shanghai CP Guojian Pharmaceutical
- 21 May 2012 Actual end date 31 Oct 2009 added as reported by Chinese Clinical Trial Register.
- 06 Sep 2009 New trial record.